Lovenox (enoxaparin sodium) Injection has been approved for the extended prevention of deep-vein thrombosis (DVT) following hip replacement surgery. It was previously approved for use in a hospital setting, and is the first low-molecular-weight heparin to be approved for once a day at home use.
In clinical studies, patients discharged for the hospital without signs of venous thromboembolic disease received either a three-week regimen of Lovenox, or placebo. Results demonstrated that the incidence of DVT during the three-week period was significantly lower in the Lovenox patients, 7% compared to 20% for placebo.
Nine percent of patients reported an incidence of injection-site hematoma (bruising).
Lovenox (enoxaparin sodium) is an antithrombotic agent known as a low-molecular-weight heparin.
The Lovenox (enoxaparin sodium) Injection drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.